spacer
home > epc > summer 2002 > coating advancements for blood-contacting devices
PUBLICATIONS
European Pharmaceutical Contractor

Coating Advancements for Blood-Contacting Devices

Most of today's blood-contacting medical devices are made of synthetic materials. When blood makes contact with these materials that are foreign to the body, a number of adverse reactions are triggered (including platelet attachment, platelet activation, and complement activation). These reactions eventually lead to fibrin production and clot formation. These clots can impair the function of the device. More drastically, they can occlude critical vessels at the implant location or be released into the patient's blood stream where they can obstruct distant blood vessels, potentially leading to strokes or even death.

Overview of Blood Compatibility

Improved compatibility with blood is a desired feature for a variety of medical devices that must contact blood during clinical use. It is difficult, however, to achieve this improvement by altering the bulk materials used for fabricating the devices. A more straightforward method is to apply a thin-film coating to the surface of the device to confer improved blood compatibility to the device.

For many years researchers have been developing coatings to improve the blood compatibility of medical devices. Heparin-based coatings have been demonstrated to substantially improve the performance of a variety of blood-contacting medical devices. Recently, non-heparin-based synthetic coatings have also shown promise for medical device applications where biological molecules are inappropriate or undesired.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Babcock, Associate Research Scientist, Amy Novak, Director of Haemocompatibility and Dr Aron Anderson, Director of Drug Delivery at SurModics, Inc.

David Babcock is an Associate Research Scientist in the haemocompatibility department of SurModics, Inc. David graduated from the University of Minnesota with a BS in Biology, concentrating on cellular and molecular biology. After graduation, he continued his work in a university research lab studying telomeric proteins. David has been a Research Scientist at SurModics since 1998 and is responsible for developing and performing tests for assessing haemocompatibility.

Amy Novak is currently Director of Haemocompatibility at SurModics, Inc., where she is responsible for the development and commercial applications of medical device coatings to improve the compatibility of blood-contacting devices. Her previous position at SurModics was Manager, Haemocompatible Commercial Applications, where she was responsible for working with customers on blood-contacting devices. Amy has a BS degree in Chemical Engineering from the University of Missouri, and has been with SurModics since January 2000. Previously, she worked at 3M Company for 10 years in various technical positions.

Dr Aron Anderson is currently Director of Drug Delivery at SurModics Inc., where he is responsible for development of medical device coatings that contain and release drug for local therapy. His previous position at SurModics was Director of Haemocompatibility where he was responsible for the development of coatings to improve the compatibility of blood-contacting devices. Aron gained a BS in Chemical Engineering from the University of Minnesota and received his PhD from Stanford University. He has been with the company since 1991.
spacer
David Babcock
spacer
spacer
spacer
Amy Novak
spacer
spacer
spacer
Dr Aron Anderson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement